Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jan 2024

Martin Isaac, McDonald Nancy, Wilson David, Ratjen Felix, Grasemann Hartmut

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles
Share to Chloride Channel Agonists
Share to Nitric Oxide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 37867075
DOI: 10.1016/j.jcf.2023.05.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis.PMID 37867075Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutationSemantic proximity Read ↗

Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?Semantic proximity Read ↗

Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.Semantic proximity Read ↗

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Semantic proximity Read ↗

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialSemantic proximity Read ↗

Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study.Semantic proximity Read ↗

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.Semantic proximity Read ↗

Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.